{"record_type":"pith_number_record","schema_url":"https://pith.science/schemas/pith-number/v1.json","pith_number":"pith:2016:AULGSYAXTOX27CJ5IYINZNK6XF","short_pith_number":"pith:AULGSYAX","schema_version":"1.0","canonical_sha256":"05166960179bafaf893d4610dcb55eb94367d6f50003da7716e62d71303724a3","source":{"kind":"arxiv","id":"1604.04913","version":1},"attestation_state":"computed","paper":{"title":"Optimized Treatment Schedules for Chronic Myeloid Leukemia","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":["math.OC","q-bio.PE"],"primary_cat":"q-bio.TO","authors_text":"David Dingli, Jasmine Foo, Junfeng Zhu, Kevin Leder, Qie He","submitted_at":"2016-04-17T19:16:17Z","abstract_excerpt":"Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations that preexist treatment can be detected in a substan- tial number of patients, and that this may be associated with eventual treatment failure. One proposed method to extend treatment efficacy is to use a combination of multiple targeted therapies. However, the design of such combination therapies (tim"},"verification_status":{"content_addressed":true,"pith_receipt":true,"author_attested":false,"weak_author_claims":0,"strong_author_claims":0,"externally_anchored":false,"storage_verified":false,"citation_signatures":0,"replication_records":0,"graph_snapshot":true,"references_resolved":false,"formal_links_present":false},"canonical_record":{"source":{"id":"1604.04913","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.TO","submitted_at":"2016-04-17T19:16:17Z","cross_cats_sorted":["math.OC","q-bio.PE"],"title_canon_sha256":"03de667e98ed74350c89864a03b62ddef0f69bf3d360d24a1a3d45d066732938","abstract_canon_sha256":"f4f49539f85e73591f7d513bd565fbcca34df4cc68a6cb121e9f85ee018d1cdb"},"schema_version":"1.0"},"receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T00:51:17.660907Z","signature_b64":"vt0s26LtnAbejCi3uAUQvmhiD3nyp9WWQcuHJ0qcSyGfNPepvR85CrId1wH65mh6gEq3yQFHoNBjBAIPLH19Aw==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"05166960179bafaf893d4610dcb55eb94367d6f50003da7716e62d71303724a3","last_reissued_at":"2026-05-18T00:51:17.660236Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T00:51:17.660236Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"graph_snapshot":{"paper":{"title":"Optimized Treatment Schedules for Chronic Myeloid Leukemia","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":["math.OC","q-bio.PE"],"primary_cat":"q-bio.TO","authors_text":"David Dingli, Jasmine Foo, Junfeng Zhu, Kevin Leder, Qie He","submitted_at":"2016-04-17T19:16:17Z","abstract_excerpt":"Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients. Recent studies have shown that resistance mutations that preexist treatment can be detected in a substan- tial number of patients, and that this may be associated with eventual treatment failure. One proposed method to extend treatment efficacy is to use a combination of multiple targeted therapies. However, the design of such combination therapies (tim"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1604.04913","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"aliases":[{"alias_kind":"arxiv","alias_value":"1604.04913","created_at":"2026-05-18T00:51:17.660358+00:00"},{"alias_kind":"arxiv_version","alias_value":"1604.04913v1","created_at":"2026-05-18T00:51:17.660358+00:00"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1604.04913","created_at":"2026-05-18T00:51:17.660358+00:00"},{"alias_kind":"pith_short_12","alias_value":"AULGSYAXTOX2","created_at":"2026-05-18T12:30:07.202191+00:00"},{"alias_kind":"pith_short_16","alias_value":"AULGSYAXTOX27CJ5","created_at":"2026-05-18T12:30:07.202191+00:00"},{"alias_kind":"pith_short_8","alias_value":"AULGSYAX","created_at":"2026-05-18T12:30:07.202191+00:00"}],"events":[],"event_summary":{},"paper_claims":[],"inbound_citations":{"count":0,"internal_anchor_count":0,"sample":[]},"formal_canon":{"evidence_count":0,"sample":[],"anchors":[]},"links":{"html":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF","json":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF.json","graph_json":"https://pith.science/api/pith-number/AULGSYAXTOX27CJ5IYINZNK6XF/graph.json","events_json":"https://pith.science/api/pith-number/AULGSYAXTOX27CJ5IYINZNK6XF/events.json","paper":"https://pith.science/paper/AULGSYAX"},"agent_actions":{"view_html":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF","download_json":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF.json","view_paper":"https://pith.science/paper/AULGSYAX","resolve_alias":"https://pith.science/api/pith-number/resolve?arxiv=1604.04913&json=true","fetch_graph":"https://pith.science/api/pith-number/AULGSYAXTOX27CJ5IYINZNK6XF/graph.json","fetch_events":"https://pith.science/api/pith-number/AULGSYAXTOX27CJ5IYINZNK6XF/events.json","actions":{"anchor_timestamp":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF/action/timestamp_anchor","attest_storage":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF/action/storage_attestation","attest_author":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF/action/author_attestation","sign_citation":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF/action/citation_signature","submit_replication":"https://pith.science/pith/AULGSYAXTOX27CJ5IYINZNK6XF/action/replication_record"}},"created_at":"2026-05-18T00:51:17.660358+00:00","updated_at":"2026-05-18T00:51:17.660358+00:00"}